SNDX Syndax Pharmaceuticals
- 20.080
- -0.200-0.99%
- 20.440
- +0.360+1.79%
Syndax Pharmaceuticals News
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $32
Barclays analyst Peter Lawson maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 44.1% a
Syndax Pharmaceuticals Price Target Maintained With a $34.00/Share by JP Morgan
Syndax Pharmaceuticals Price Target Maintained With a $34.00/Share by JP Morgan
Komo: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $34.00 to $34.00.
Komo: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $34.00 to $34.00.
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target
JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals with a Overweight and maintains $34 price target.
Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions
Press Release: Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors PR Newswire WALTHAM, Mass., May 15, 2024 WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (
Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus
Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30
Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $32 to $30.
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Stifel
Syndax Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Stifel
Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.
Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate
Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals Q1 Net Loss Widens
Syndax Pharmaceuticals (SNDX) reported a Q1 net loss Wednesday of $0.85 per diluted share, wider than a loss of $0.59 a year earlier. Analysts polled by Capital IQ expected a loss of $0.97. The compan
Syndax Pharmaceuticals Q1 2024 GAAP EPS $(0.85) Beats $(0.99) Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(0.99) by 14.14 percent. This is a 44.07 percent decrease over losses
Syndax Pharmaceuticals | 10-Q: Quarterly report
Syndax Pharmaceuticals 1Q Loss/Shr 85c >SNDX
Syndax Pharmaceuticals 1Q Loss/Shr 85c >SNDX
Syndax Pharmaceuticals 1Q Loss $72.4M >SNDX
Syndax Pharmaceuticals 1Q Loss $72.4M >SNDX
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), BioCryst (BCRX) and Syndax Pharmaceuticals (SNDX)
Analysis
Price Target
No Data
